Products and Services

Product Licensing & Distribution Opportunities

Product Licensing & Distribution Opportunities

Aptalis Pharmaceutical Technologies has a number of Rx and OTC products available for licensing. In general, these products are new formulations of existing drugs that incorporate one or more of our proprietary drug delivery technologies. We license these products to pharmaceutical companies for marketing throughout the world.

Currently more than 40 products have been developed by Aptalis Pharmaceutical Technologies and are commercialized by our partners in different countries around the world. These products span a range of key therapeutic categories, including:

• Gastrointestinal (GI)
• Cardiovascular
• CNS
• Pain
• Respiratory
• Nutrition

Contact Us (partners@AptalisPharma.com) to discuss available licensing opportunities.

Validated Pharmaceutical Technology Platforms

Aptalis Pharmaceutical Technologies develops products for our partners and for our own portfolio utilizing our core technology platforms:

Taste-Masking & Orally Disintegration Tablets (ODT)

• Microcaps® – Superior taste-masking of bitter drugs via microencapsulation using a proprietary coacervation technique to create a uniform, precise coating of drug particles
• AdvaTab® – Patient-friendly orally disintegrating tablet (ODT) technology that meets FDA guidance regarding ODTs, including rapid (<30 sec) disintegration in the mouth with or without liquid

Customized Drug Release

• Diffucaps® – Flexible multiparticulate system facilitates the development and commercialization of optimal release profiles for single drugs and drug combinations
• Eurand Minitabs® – Tiny cylindrical matrix tablets that act as multiparticulates and can be utilized for combination products with multiple release profiles
• Diffutab®- Matrix tablets that provide sustained release via a combination of water-soluble particles with active drug; well-suited for delivery of high-dose products and sustained release and/or once-daily dosing

Bioavailability Enhancement for Poorly Soluble Drugs

• Biorise® – Enhances bioavailability by improving the solubility of certain drugs, resulting in faster onset of action and improved bioavailability

Partnering With Aptalis Pharmaceutical Technologies

Through our collaboration agreements, we have successfully applied our technologies to drug products in a diverse range of therapeutic areas, resulting in a broad portfolio of Rx and OTC products available for out-licensing.

Our partnership process provides our clients with an experienced management team across all functions and stages of the product development cycle. We have a multinational infrastructure and integrated R&D and manufacturing facilities in the U.S. and Europe, allowing us to offer global solutions to companies in various regions around the world.

In addition, our global business development and licensing teams strive to offer flexible deal structures to maximize our partners’ interests.

To meet our partners’ business needs, we offer resources for the development of new product formulations, or licensing availability of existing product formulations.

Partner Portfolio

We have established partnerships with major pharmaceutical companies, including Eisai, GlaxoSmithKline, Nycomed, Pfizer, Samil, sanofi-aventis, Teva, UCB, Abbott, Actavis, Adcock Ingram, Aliud, Bayer, Bristol-Myers Squibb, Cephalon, Daewoong, Johnson & Johnson, Menarini, Merck, and Novartis. These relationships are based on either co-development of products using our partners’ drug and our pharmaceutical technologies, or the licensing and distribution of our internally developed products.

Partner in the lifecycle management of your product portfolio.
Contact us atwww.AptalisPharmaceuticalTechnologies.com/contact.html